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Objective: Previous studies have demonstrated that suppression of Nrf2 in
Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial
dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator
and NF-kB suppressor, targets dysfunctional inflammatory, metabolic, and
bioenergetic pathways. The dose-ranging portion of this Phase 2 study assessed
the safety, pharmacodynamics, and potential benefit of omaveloxolone in
Friedreich ataxia patients (NCT02255435). Methods: Sixty-nine Friedreich
ataxia patients were randomized 3:1 to either omaveloxolone or placebo admin-
istered once daily for 12 weeks. Patients were randomized in cohorts of eight
patients, at dose levels of 2.5–300 mg/day. Results: Omaveloxolone was well
tolerated, and adverse events were generally mild. Optimal pharmacodynamic
changes (noted by changes in ferritin and GGT) were observed at doses of 80
and 160 mg/day. No significant changes were observed in the primary outcome,
peak work load in maximal exercise testing (0.9  2.9 W, placebo corrected).
At the 160 mg/day dose, omaveloxolone improved the secondary outcome of
the mFARS by 3.8 points versus baseline (P = 0.0001) and by 2.3 points versus
placebo (P = 0.06). Omaveloxolone produced greater improvements in mFARS
in patients that did not have musculoskeletal foot deformity (pes cavus). In
patients without this foot deformity, omaveloxolone improved mFARS by 6.0
points from baseline (P < 0.0001) and by 4.4 points versus placebo (P = 0.01)
at the 160 mg/day. Interpretation: Treatment of Friedreich ataxia patients with
omaveloxolone at the optimal dose level of 160 mg/day appears to improve
neurological function. Therefore, omaveloxolone treatment is being examined
in greater detail at 150 mg/day for Friedreich ataxia.
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1
Introduction
Friedreich Ataxia (FRDA) is a progressive, life-shorten-
ing ataxia caused by mutations in FXN, which codes
for the protein frataxin.1–4 The primary features of the
disorder include progressive loss of coordination and
ambulation, fatigue, cardiomyopathy, and metabolic dis-
turbances. Scoliosis and other skeletal abnormalities are
also found in many individuals. The exact mutation is
homozygosity for an expansion of an intronic GAA
repeat in 96% of patients, with the others having a sin-
gle expansion with a point mutation in FXN on the
opposite allele. Although most patients present within
the first 15 years, some present later, and in all FRDA
is a lifelong disease.5,6 Although the complete patho-
physiology is unclear, there is substantial evidence of
mitochondrial dysfunction in FRDA. Frataxin is directed
to the mitochondria, where it is thought to play impor-
tant roles in synthesis of iron sulfur clusters and ATP
production. In addition, cells from patients with FRDA
are susceptible to reactive oxygen species production.
Surprisingly, Nrf2 activation is suppressed in FRDA-
derived cells, potentially contributing to oxidative stress,
mitochondrial dysfunction, and reduced ATP produc-
tion in FRDA.7–10 Augmentation of Nrf2 activation
using a variety of compounds increases Nrf2 activation
and reverses endogenous antioxidant defense mecha-
nisms in animal and cellular models of FRDA. This
makes the Nrf2 pathway a potential therapeutic target
in FRDA.
Omaveloxolone (Omav) is a new Nrf2 activator that
prevents the ubiquitination of Nrf2 and thus increases
its levels. In cell culture, Omav induces Nrf2 as mea-
sured by levels of the downstream target NQO1.11 In
cells from patients with FRDA, Nrf2 activation
increases mitochondrial function as measured by mito-
chondrial transmembrane potential and reverses bio-
marker levels in lymphoblasts.12,13 In these systems,
concentration-response curves demonstrate concentra-
tion-dependent increases, followed by a plateau at
higher concentrations, and then a decline in effect at
still higher concentrations with loss of cell viability.14
This loss of activity at high concentrations is also
observed in other settings with Nrf2 activators, as cel-
lular redox status is tightly regulated to prevent exces-
sive oxidative or reductive stress.14 In the present
study, designated MOXIe, we assessed the pharmacoki-
netics, safety, pharmacodynamics, and clinical effects of
Omav in FRDA over 12 weeks to establish whether it




The study (NCT02255435) was approved by the Institu-
tional Review Board at the Children’s Hospital of
Philadelphia and other sites, and written informed con-
sent was obtained from the patient before any study-
related procedures were performed. Subjects were enrolled
from January 2015 to February 2017 at the Children’s
Hospital of Philadelphia; the University of California Los
Angeles; Ohio State University; Emory University; the
University of South Florida; Murdoch Children’s Research
Institute; University College, London; Medical University,
Innsbruck, and the University of Florida. MOXIe was
designed as a two-part study. Part 1, presented here, was
a Phase 2, double-blind, randomized, placebo-controlled,
dose-ranging, multi-center trial (Fig. 1) while Part 2 has
been designed to assess efficacy and safety. The sample
size for Part 1 was based on a dose-escalation scheme to
evaluate initial safety, PK, and PD activity of RTA 408 in
this patient population. The small number of patients at
each dose in Part 1 was not expected to fully characterize
safety, efficacy, or PD, but rather inform the DSMB and
Sponsor of the appropriate doses to select for Part 2. In
Part 1, cohorts of 8 patients at ascending dose levels were
screened, randomized 3:1 to Omav or placebo, and trea-
ted for 12 weeks. Two cohorts were enrolled at 160 mg/
day (12 Omav and 4 Placebo), and two cohorts were
enrolled at 300 mg/day with the final cohort enrolling
only five patients (resulting in 10 Omav and 3 Placebo in
the 300 mg/day cohort; discontinued due to sufficient
safety data being obtained). Safety was overseen by a Data
Safety and Monitoring Board. Multiple clinical assess-
ments of muscular and neurological function were
assessed in Part I including neuromuscular endpoints
(peak work during exercise testing, the primary endpoint,
assessed at baseline and 12 weeks); neurological abilities
(assessed by the mFARS, a key secondary endpoint,
assessed at baseline 4 and 12 weeks); performance mea-
sures (the timed 25 foot walk test, nine hole peg test, low
contrast vision, assessed at baseline and 12 weeks); health
related quality of life (SF-36 Health Survey Update,
assessed at baseline and Week 12); and laboratory testing
for safety and biochemistry, assessed at baseline, 1, 2, 4,
8, and 12 weeks during the study.
Eligibility criteria
Patients were required to have genetically confirmed
Friedreich’s ataxia with an mFARS score ≥10 and ≤80, be
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≥16 years of age, and ≤40 years of age. They also needed
the ability to complete maximal exercise testing, defined
by being able to ride an exercise ergometer at approxi-
mately 60 rpm against no added resistance for 3 min.
Patients were excluded if they had uncontrolled diabetes
(HbA1c >11.0%), B-type natriuretic peptide (BNP) level
>200 pg/mL, or a history of clinically significant cardiac
disease. They were required to discontinue all antioxidant
supplements at least 14 days prior to baseline.
Randomization and masking
When subjects met inclusion criteria, they were random-
ized by computer generated program at 3:1 for each dose
group. Subjects and all study staff were masked to subject
assignment. Fifty-two patients were randomized to Omav
at doses of 2.5–300 mg/day, and 17 patients were ran-
domized to placebo.
Outcome measures
The primary outcome measure was the peak work
attained during maximal exercise testing, along with the
safety and tolerability of Omav. Key secondary outcome
measures included the mFARS score.5,15 Exploratory
measures included the SF-36 Health Survey Update
score; the Fatigue Severity Scale score, 9-hole peg test,
the timed 25-foot walk test, low-contrast letter visual
Figure 1. Consort diagram of MOXie, part 1.
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acuity test, and peak oxygen utilization during maximal
exercise testing.15 Pharmacodynamic markers included
protein and enzyme (AST, GGT, CK, and ferritin) levels
in serum samples, and assessment of platelet metabolism
with 13C-isotopologues.16 Isotopologue analysis was per-
formed only in subjects evaluated at the primary site
(CHOP). Safety measures included weight, BMI, vital
sign measurements, physical examinations, laboratory
test results (clinical chemistry, hematology, and urinaly-
sis), concomitant medications, adverse events, and seri-
ous adverse events. Pharmacokinetic measures included
Omav plasma concentration levels. Disease features such
as the presence of pes cavus were ascertained by physical
examination.
Maximal exercise test
Cycle ergometry using a recumbent stationary bicycle was
used to conduct maximal exercise testing. Maximal exer-
cise testing assessments included peak work and peak
oxygen utilization. On study days where multiple assess-
ments were completed, the maximal exercise test was the
first functional assessment performed.
Neurological testing
The FARS was used as the neurological measure. This
includes five sections that measure upper and lower limb
coordination, upright stability, bulbar function, and
peripheral nervous system function. The mFARS used
here omits the peripheral nervous system components so
that all remaining assessments are functional tests. The
testing was performed as described previously.5,17–19 The
timed 25 foot walk (T25W), SF36, low contrast letter
acuity, and the 9 hole peg test (9HPT) were performed as
described previously.17
Statistical analysis
Peak work, mFARS, percent change from baseline in labo-
ratory parameters, and the 25-foot timed walk test were
analyzed using repeated measures analysis of variance.
Analysis visits at baseline, week 4, week 8, and week 12 were
used in the repeated measures analysis, with an unstruc-
tured covariance structure. Adjustment for baseline weight
was utilized in the analysis of peak work. The pairwise dose
group comparisons with placebo were estimated using the
difference in adjusted means and 95% confidence intervals
for the difference in changes from baseline to Week 12. Sig-
nificance of Week 12 median change from baseline in cre-
atine kinase was evaluated using a one-way ANOVA. For
isotopologue analysis, cohorts were pooled into placebo
(n = 3), cohorts 1 and 2 (n = 8) and cohorts 3–8 (n = 13)




Sixty-nine patients were enrolled, with baseline character-
istics generally balanced across treatment groups. The
mean age at study entry was 25.6 years and at diagnosis
was 15.3 years. Ninety percent of patients were ambula-
tory, and the cohort had a mean mFARS of 41.1
(Table 1). Examining the age at onset and other features,
this cohort is slightly less affected than average in large
natural history studies.17
Table 1. Demographic and clinical features of cohort.
Placebo Omav All
N 17 52 69
Sex (% Female) 10 (59%) 27 (52%) 37 (54%)
Age (years) 24.4  6.7 (16–37) 25.9  6.4 (16–37) 25.6  6.5 (16–37)
BMI (kg/m2) 22.4  3.7 (16.2–31.5) 24.2  4.9 (17.4–38.7) 23.7  4.7 (16.2–38.7)
Race(% White) 16 (94%) 51 (98%) 67 (97%)
Age at Onset (years) 16.6  4.7 (11–27) 14.8  4.8 (6–30) 15.3  4.8 (6–30)
Duration (years) 7.7  3.5 (0–10) 11.1  5.3 (0–16) 10.3  5.1 (0–16)
GAA1 repeat length 863  278 (333–1300) 700  277 (216–1350) 741  285 (216–1350)
GAA2 repeat length 620  304 (19–1050) 714  274 (200–1333) 690  282 (19–1333)
Ambulatory 16 (94%) 46 (89%) 62 (90%)
Pes cavus 10 (59%) 22 (42%) 32 (46%)
Areflexia 13 (77%) 42 (81%) 55 (80%)
Scoliosis surgery 3 (18%) 6 (12%) 9 (13%)
Modified FARS 40.5  10.0 (22.5–53.8) 41.3  12 (10.7–59.5) 41.1  11.5 (10.7–59.5)
Values are mean + SD with quartile ranges in parentheses where indicated.
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Safety, tolerability, pharmacokinetics, and
pharmacodynamics
Omav was well-tolerated with only a single discontinua-
tion, which occurred in a 40 mg/day patient who devel-
oped a skin rash. One placebo patient discontinued
prematurely due to withdrawal of consent. Overall,
adverse events were generally mild in severity, and most
prominently included an increased number of upper res-
piratory tract infections and nasopharyngitis (Table 2). A
limited number of subjects demonstrated ALT and AST
increases. However, these were not associated with any
signs or symptoms of liver injury (increased direct biliru-
bin, decreased albumin, changes in total protein) and are
expected as isolated pharmacological effects of Nrf2 acti-
vation.20,21 Two serious adverse events were reported,
both of which occurred in placebo patients (benzodi-
azepine withdrawal and 3rd degree burns).
Pharmacokinetic testing demonstrated generally dose-
dependent, linear increases in exposure (Fig. 2). The Cmax
at 300 mg/day was in the concentration range where
decreased Nrf2 induction and mitochondrial function
have been observed in vitro.22–25 Pharmacodynamically,
Omav commonly alters a series of Nrf2 targets such as
ferritin and GGT in vitro and in other human studies.20–
25 Thus we monitored these targets during the present
study. Dose-dependent changes in these were observed
with Omav, with the most robust changes occurring at 80
-300 mg/day; such changes were maximal after 4 weeks of
administration (Fig. 3). Similarly aspartate amino trans-
ferase (AST) and creatine kinase (CK) are indirectly regu-
lated by Nrf2.20,21 AST variably increased at lower doses
and was maximal at 160 mg/day while optimal CK
decreases were observed at 80–160 mg/day with reduced
improvement at 300 mg/day.
Individuals with FRDA also have altered metabolism,
which can be quantified with ex vivo isotopologue analy-
sis in isolated platelets.16,19 Such analysis reveals an
increased conversion of 13C-palmitate to HMG-CoA. In
subgroup at the primary site, isolated platelets revealed
lower conversion of 13C-palmitate to HMG-CoA as Omav
dose increased (Fig. 4). As for other pharmacodynamic
markers, this effect was maximal and significant at
160 mg alone (data not shown), and significant when
cohorts were pooled (Fig. 4). No changes were seen in
metabolism to beta-hydroxy-butyrate or acetate, and no
changes in metabolism of 13C-glucose were noted.
Effect of Omav on clinical testing in FRDA
Exercise and mFARS testing
No statistical difference in peak workload (the primary
outcome measure) was found with Omav treatment versus
placebo or relative to baseline (P = 0.77 vs. placebo for all
Omav dose groups) (Table 3). A nonsignificant increase in
peak work occurred at 160 mg/day compared to baseline.
In contrast, Omav significantly improved mFARS scores
from baseline in a dose-dependent manner (P < 0.001)
(Fig. 5; Table 4). Overall, dose-dependent improvements
at Week 12 were maximal at 160 mg/day. When compared
to the placebo-corrected change at 160 mg/day (2.3), the
improvement in mFARS approached statistical significance
(P = 0.06) and was equivalent to an improvement of
about 1 year of progression in FRDA based on compar-
isons to natural history data.15,17 The improvements in
mFARS were time dependent, as the mFARS improved by
week 4 and further improved by week 12. In addition, the
improvement compared to placebo increased over this
time. Interestingly, mFARS changes mirrored AST induc-
tion and isotopologue results, since all responses were
maximal at doses of 80–160 mg/day and decreased
between 160 and 300 mg/day.
After 12 weeks of treatment, patients treated with
Omav 160 mg/day did not show improvements versus
placebo in 9-hole peg test time for dominant (P = 0.20)
or nondominant hand (P = 0.89), 25-foot timed walk test
(P = 0.64), 1/25-foot timed walk test (P = 0.85), low-con-
trast letter acuity test (P = 0.93), or SF-36 (P = 0.19).
Association of OMAV response with disease
features in FRDA
We then sought to ascertain if any features of FRDA pre-
dicted a greater response to Omav. Patients with FRDA
can develop pes cavus, also referred to as neuromuscular
foot deformity. In the present study, the absence of pes
cavus was associated with larger improvements in mFARS
exam, including a placebo-corrected change in mFARS in
Table 2. Adverse events.






Upper respiratory tract infection 21 (40%) 1 (6%)
Headache 9 (17%) 3 (18%)
Ligament sprain 1 (2%) 2 (12%)
Abdominal pain upper 1 (2%) 3 (18%)
Nasopharyngitis 7 (14%) 0 (0%)
Fatigue 4 (8%) 2 (12%)
Diarrhea 6 (12%) 1 (6%)
Alanine aminotransferase increased 6 (12%) 0 (0%)
Aspartate aminotransferase increased 6 (12%) 0 (0%)
Constipation 1 (2%) 2 (12%)
Nausea 5 (10%) 1 (6%)
Arthralgia 5 (10%) 0 (0%)
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patients without pes cavus of 4.4 points (P = 0.01) at
Omav 160 mg/day (Fig. 6). Placebo-related change in
mFARS was unaffected by the presence of pes cavus. In
exercise testing in patients on 160 mg/day who did not
have pes cavus, peak workload increased 11.5 W (95% CI
1.1, 21.9), which was significant vs. baseline (P = 0.03).
In addition, absence of pes cavus was associated with a
greater improvement in the 25-ft walk test and exercise
testing compared with placebo.
We also examined the relation of a series of other dis-
ease features to responsiveness to Omav, including age of
onset, disease duration, GAA1 (shorter) and GAA2
(longer) repeat length, sex, ambulation assist type, prior
scoliosis surgery, and age. In contrast to the association
with pes cavus, none had a clear relationship to response
on Omav. Age of onset, age, disease duration, GAA1
repeat length and GAA2 repeat length did not correlate
with improvements in mFARS in Omav-treated patients.
Omav-treated patients also showed no significant differ-
ence in mFARS as a function of ambulation status
(P = 0.97), sex (P = 0.71), prior scoliosis surgery
(P = 0.86), and ambulation assist type (P = 0.51).
Discussion
The present study demonstrates that Omav remains a
viable therapeutic agent for ongoing development in
FRDA, as it was well tolerated and associated with rela-
tively few adverse events. In addition, although it had no
effect on the primary outcome of measure of peak work
Figure 2. Pharmacokinetics of Omav. Maximal concentration of Omaveloxolone Cmax levels are shown at different doses. Data are presented as a
Box and whisker plot. Plasma concentrations increased exponentially over the dose range of the study.
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in exercise testing, Omav led to a dose-dependent
improvement in pharmacodynamic measures and neuro-
logical function as measured by the mFARS exam. Finally,
Omav improved selected other measures to a modest
degree in this short study. The dose dependence of Omav
was concordant across clinical and pharmacodynamic
measures, and was in the range expected based on
in vitro studies. Consequently, the present data create a
solid rationale for further clinical trials of Omav.
The present data correspond with the proposed role of
Nrf2 suppression in FRDA. Nrf2 fails to undergo nuclear
translocation in cellular models of FRDA, and in mice
with FRDA, downstream targets of Nrf2 are decreased,
consistent with downregulation of the pathway.7–10 This
may reflect increases in Keap1, which regulates
ubiquitination of Nrf2 and thus its turnover. In addition,
several different Nrf2 targets are downregulated in
patients with FRDA, including ferritin, whose levels are at
the lower end of normal in FRDA.26,27 There have been
previous suggestions that topical Nrf2 application could
reverse Nrf2 suppression and improve frataxin levels in
FRDA.7 Nrf2, its downstream pathways, and frataxin were
not directly measured in the present study, but other
Nrf2 targets including GGT and AST were altered by
Omav, demonstrating the activation of Nrf2. Although
other Nrf2 related agents are clinically approved for other
diseases, their relative tolerability is modest and in vitro
potency lower.28 Thus Omav is likely to provide superior
results in clinical studies in FRDA compared with other
available Nrf2 activators. In the present study, the
Figure 3. Pharmacodynamic effects of Omav. Omav had dose dependent effects on Ferritin (A), GGT (B), AST (C) and creatine kinase (D). In
general, effects of Omav increased through doses of 180 mg, then were blunted at the highest dose (300 mg).
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pharmacodynamic, pharmacokinetic, and beneficial
responses all maximized at the 160 mg dose, suggesting it
may provide the appropriate dose in future studies.
In this study, a variety of commonly measured clinical
laboratory values served as pharmacodynamic markers of
Nrf2 activation. The increase in ferritin is particularly
interesting, as ferritin levels are relatively suppressed in
FRDA. Changes in AST and GGT are initially perplexing,
but most likely do not represent liver dysfunction.
Transaminases are not liver-specific, but is expressed in
other tissues, and also play a role in glucose metabolism
by catalyzing the conversion of a-ketoglutarate to gluta-
mate.20 The profile of transaminase increases with Omav
is similar to those reported in response to a high-carbo-
hydrate, high-calorie diet in healthy volunteers.20 Thus,
the increases in transaminases with Omav may reflect
improvements in glucose metabolism. Still, such changes
have the potential for unblinding study staff. In the pre-
sent study, laboratory results were delivered days after
evaluations were performed and were only viewed by staff
monitoring adverse events, minimizing the chance of
unblinding. In the ongoing study of Omav, neurological
evaluators specifically remain blinded by specifically not
viewing laboratory studies.
In the present study, individuals without pes cavus
showed greater improvement in mFARS as well as several
other measures, while other disease features such as GAA
repeat length, disease duration and age were not associ-
ated with greater improvements in mFARS. Although the
relationship with pes cavus was not absolute (subjects
with pes cavus improved overall, but not as much as
those without this finding) and the size of the overall
cohort was modest, the effect of pes cavus did occur
across multiple measures. There are several possible expla-
nations for this phenomenon. First, pes cavus might
interfere with some of the measures (particularly exercise
testing), making it more difficult to appreciate a response.
Alternatively, as pes cavus affects the majority of FRDA
patients and is largely developmental in nature, its pres-
ence might identify a subgroup with a relatively large
fixed dysfunction that does not improve in short term
Figure 4. Platelet isotopologue analysis. Isotopic incorporation from [13C6] glucose (A) and [
13C16] palmitate (B) to HMG-CoA (%) was
determined in subjects at different dose of Omav. Cohorts were pooled into placebo (n = 3), cohorts 1 and 2 (n = 8) and cohorts 3-8 (n = 13)
for analysis due to the small number of participants in each individual cohort.




















1Values are least-squared means from mixed effect model repeat
measurement (MMRM) analysis, adjusted for baseline weight, and
treatment group, time, and the interaction between treatment and
time as fixed factors.
2Change from baseline at Week 12 compared to zero.
3Change from baseline at Week 12 in Omav patients compared to
placebo subjects.
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studies. Another possibility that the true variable is not
pes cavus but another related entity not assessed in the
present study. Within the present analysis, pes cavus was
one of a variety of potential stratifiers that were tested
and its presence was not balanced between placebo and
active agent, leading to potential artifactual associations.
Longer duration studies including larger cohorts may bet-
ter address these possibilities and assess whether this dif-
ferentiation persists with longer Omav administration.
The present study is limited slightly by the cohort fea-
tures, including its small size at any given dose and in
individual subgroups. The subjects were largely ambula-
tory and included no children, thus not directly address-
ing some subgroups of FRDA patients. In addition,
although the cohort in general resembled large natural
history populations, the mean GAA repeat length was
slightly shorter than that of other cohorts.5
In the past 10 years, a variety of agents (particularly
antioxidants) have been moderately successful in early
studies in FRDA yet failed in phase III studies.29–36 The
reasons for this have included the paroxysmally small pla-
cebo response in initial studies, the absence of a placebo
group in initial studies, and the short duration of initial
studies. The present study noted a placebo effect consis-
tent with previous studies, yet benefit was seen above that
level. In addition, the 3 month duration of the present
study is longer than in several other early studies. As with
other proposed agents in FRDA (idebenone, interferon
gamma, A0001) that have shown some short term
response, the anatomical site of action of Omav is not
entirely clear, Mitochondrial abnormalities that might be
ameliorated by Omav exist in skeletal muscle, a location
in which rapid metabolic improvement could occur.
However, Omav may also be able to enter the CNS and
peripheral nerve, where longer term slowing of neurode-
generation might be possible and immediate effects are
Figure 5. Effect of Omav on mFARS exam results. Omav produced a dose dependent improvement in mFARS score. The difference was more
apparent at the higher doses in the study, with less benefit at 300 mg, consistent with AST, ferritin, GGT and CK changes at 300 mg.
Table 4. Mean mFARS change1.
Treatment N








7 1.6  1.1 (3.9, 0.7) –
P = 0.17
All Omav 30 3.3  0.5 (4.4, 2.1) 1.7  1.3 (4.2, 0.9)
P < 0.001 P = 0.19
80 mg 4 4.2  1.3 (6.9, 1.6) 2.7  1.6 (6.0, 0.7)
P = 0.003 P = 0.11
160 mg 4 6  1.3 (8.6, 3.3) 4.4  1.6 (7.7, 1.1)
P < 0.0001 P = 0.01
Treatment with Pes Cavus
All
Placebo
10 1.2  1.0 (3.4, 0.9) –
P = 0.25
All Omav 22 1.5  0.7 (2.9, 0.2) 0.3  1.2 (2.9, 2.2)
P = 0.03 P = 0.81
80 mg 2 0.2  2.3 (4.9, 4.6) 1.2  2.5 (4.1, 6.4)
P = 0.94 P = 0.65
160 mg 8 2.7  1.2 (5.0, 0.3) 1.3  1.6 (4.5, 2.0)
P = 0.03 P = 0.42
1Values are least-squared means from mixed effect model repeat
measurement (MMRM) analysis, adjusted for treatment group, time,
and the interaction between treatment and time as fixed factors.
2Change from baseline at Week 12 compared to zero.
3Change from baseline at Week 12 in Omav patients compared to
placebo patients.
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not as readily explained. Consequently, although the effect
of Omav in longer term studies must be tested and its site
of action identified, the present study provides a solid
rationale for optimism in future studies.
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